Arbovirus infection

disease
On this page

Also known as Arboviral diseaseARBOVIRUS INFECTArbovirus InfectionsArthropod-borne viral infectionInfection, ArbovirusInfections, Arbovirus

Summary

Arbovirus infection (MONDO:0020731) is a disease and 16 clinical trials. Top therapeutic interventions include baricitinib. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namearbovirus infection
Mondo IDMONDO:0020731
EFOEFO:1001269
MeSHD001102
NCITC34396
SNOMED CT40610006
UMLSC0003723
MedGen389
Is cancer (heuristic)no

Also known as: Arboviral disease · ARBOVIRUS INFECT · arbovirus infection · Arbovirus Infections · Arthropod-borne viral infection · arthropod-borne viral infection · Infection, Arbovirus · Infections, Arbovirus

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseaseviral infectious diseasearbovirus infection

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified14
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07543458PHASE3NOT_YET_RECRUITINGTherapeutics for Moderate and Severe Dengue
NCT00116766PHASE2COMPLETEDField Evaluation of Plant-based Mosquito Control
NCT04615364Not specifiedRECRUITINGGenetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
NCT04619823Not specifiedRECRUITINGVirological and Immunological Determinants of Arbovirus Infection in New Caledonia
NCT06599970Not specifiedACTIVE_NOT_RECRUITINGImproving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility
NCT06651372Not specifiedACTIVE_NOT_RECRUITINGThe Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
NCT07229677Not specifiedRECRUITINGCohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.
NCT07291206Not specifiedRECRUITINGARBOspot: Characterization of Arbovirus Specific T Cell Response in Patients by Using Enzyme Linked Immunospot (ELISpot) Assays
NCT07412977Not specifiedNOT_YET_RECRUITINGPregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort
NCT01868399Not specifiedCOMPLETEDPilot Survey of Dengue Fever in Solomon Islands
NCT03210363Not specifiedCOMPLETEDSero-epidemiology of Priority Arboviruses in French Guiana
NCT03552094Not specifiedUNKNOWNWorld Mosquito Program Noumea - Human Sample Component
NCT03553277Not specifiedCOMPLETEDSpatial Repellents for Arbovirus Control
NCT04954352Not specifiedUNKNOWNHuman Epidemiology of Newly Identified Arboviruses
NCT05452447Not specifiedCOMPLETEDSpatial Repellents for Aedes-borne Virus Control in Sri Lanka
NCT06268691Not specifiedCOMPLETEDSustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BARICITINIB41
CHEMBL542785401
CHEMBL543550001